Hot Topics of Discussion in the Management of Multiple Myeloma Oncology Nurse Reflects on Multiple Myeloma Awareness Month
Gina Columbus reports on an FDA approval in small cell lung cancer, a partial clinical hold on multiple myeloma trials, an addition NCCN Guidelines & Black Representation | Craig Cole, MD | #IMS2025 Promising next-generation novel agents and use of genomics or genetics to select patients to give patients the right medicine for
Join us for the NCCN 2024 Annual Congress: Hematologic Malignancies in New York City from September 20 - 21! Shaji Kumar FDA Approval in SCLC, Partial Hold in Myeloma Trials, NCCN Guideline Update in CRC, and More
New Thinking on Asymptomatic Myeloma Jens Hillengass, MD, professor of oncology and internal medicine, chief of myeloma, Roswell Park Comprehensive Cancer
NCCN Guidelines in Practice™. Earn CME/CE and MOC credits for using the NCCN Guidelines to research your patient care decisions and clinical questions by This content has been developed for healthcare professionals only. Patients who seek health information should consult with their Several different forms of melanoma are discussed by Daniel G. Coit, MD, from Memorial Sloan-Kettering Cancer Center in this
What are the most recent updates to the NCCN Guidelines for CML? Co-hosted with our friends at the ECD Global Alliance, this webinar discussed the guidelines that can help improve the quality of Selinexor Combinations in Clinical Trials with Dr. Jeffrey Zonder
Recommendations for the treatment of newly diagnosed multiple myeloma based on the National Comprehensive Cancer Different forms of melanoma explored video Join Dr. Giralt as he explains the new recommended baseline workup tests for multiple myeloma. Join our online communities to
NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025 in NCCN Guidelines® Insights: Multiple Myeloma, Version 1.2025 Panelists Keith Stewart, MD, CHB; C. Ola Landgren, MD, PhD; Rafael Fonseca, MD; and Jatin P. Shah, MD, discuss the criteria for
Dr. Susan O'Brien discusses the most recent updates to the NCCN Guidelines for CML. Join our online communities to begin Different melanoma cell types may determine response to treatment video Updating the NCCN guidelines for the diagnosis and treatment of MGUS and SMM
NCCN Guidelines® Insights - Multiple Myeloma, Version 1.2025 Multiple Myeloma heme malignancies BCOP 2021
The NCCN Guidelines for Multiple Myeloma (MM) provide recommendations for diagnosis, initial workup, treatment, follow-up, and supportive care for patients NCCN Guidelines for Patients: Multiple Myeloma
Promising treatments are available for patients with multiple myeloma, some of which are briefly reviewed by cancer expert Discussion of clinical trial data and NCCN Guidelines for the use of drug therapies in standard-risk myeloma. For more resources Overview of the updated NCCN Clinical Practice Guidelines for systemic AL amyloidosis
Comment or message if you have content you want me to share. Make everything public instead of hiding it behind paywall! Transplant Patients' Options, CoMMpass Study, and Doublet Versus Triplet Therapy
Kenneth C. Anderson, MD, Giant of Cancer Care: Myeloma, Dana-Farber Cancer Institute/Brigham and Women's Cancer Center, NCCN 2024 Hematologic Malignancies Congress: Dr. Shaji Kumar To Discuss Advances in Multiple Myeloma
The NCCN Guidelines for Multiple Myeloma (MM) provide recommendations for diagnosis, initial workup, treatment, follow-up, and supportive Cancer Nursing Today contributor and hematologic oncology nurse Alicia Michaelsen, BSN, RN, BMTCN®, speaks about Multiple
Multiple myeloma explained video Discussing how to treat MGUS (Monoclonal gammopathy of undetermined significance) and Smoldering Myeloma using an
Multiple Myeloma. NCCN Guidelines in Practice™. Earn CME/CE and MOC credits for using the NCCN Guidelines to research your patient care decisions and clinical The key opinion leaders discuss the need for transparency between the National Comprehensive Cancer Network (NCCN) Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO, of the Cleveland Clinic Taussig Cancer Institute and Case
Cancer expert Kenneth C. Anderson, MD, from Dana-Farber Cancer Institute discusses bone marrow transplantation techniques Preview: Promising Phase III Myeloma and NSCLC Trials, FDA Approval Sought in MZL, and More
The new standard of care in #multiplemyeloma is giving 4 drug therapy Shaji Kumar, MD, Mayo Clinic, Rochester, MN, discusses updates in the National Comprehensive Cancer Network (NCCN) Multiple Myeloma - Guidelines Detail
"We don't save the best for last like we might see in a romantic movie." The new standard of care in #multiplemyeloma is giving 4 Video: How is multiple myeloma treated?
Watch the full course and our most up-to-date content here: Create a free account to track Multiple myeloma is a cancer that forms in a type of white blood cell called a plasma cell. Healthy plasma cells help fight infections
The NCCN Guidelines for MM provide a framework on which to base decisions regarding workup, treatment, and follow-up of newly diagnosed and previously treated Multiple Myeloma. Version: 4.2026. Myelodysplastic Syndromes. Version: 1.2026 NCCN MAKES NO REPRESENTATIONS OR WARRANTIES CONCERNING THE NCCN CONTENT, THE
Case 1: Choosing the Right Therapy for Standard-Risk Myeloma How Nurses Can Educate Patients About Multiple Myeloma PROF OF MEDICINE ROBERT ORLOWKSI OF MD ANDERSON CANCER CENTER, HOUSTON, USA gave lecture on NEWLY
It is important to know that not all metastatic breast cancers are the same. Testing helps plan treatment designed just for you. Thomas C. Shea, MD will describe what these diseases are and how they manifest in most patients, the sort of general treatments
How multiple myeloma affects patients video First line treatment for multiple myeloma (4-drug combinations) better results #knowmyeloma What Are The Stages Of Multiple Myeloma?
Multiple Myeloma Symposium -- Full Video Treatment by Cancer Type What are the latest updates to the NCCN guidelines for the management of MM?
Promising areas of research in multiple myeloma video Understanding the NCCN Guidelines® for Histiocytosis in Adults Webinar - June 2021
Caring for the Patient with Leukemia, Lymphoma, or Multiple Myeloma - T. Shea - 20180326 NCCN Patient Webinar: Multiple Myeloma
NCCN Patient Webinar: CAR T-Cell Therapy for Lymphoma and Side Effects Managing Discrepancies in NCCN and Payer Guidelines in MM Ide-Cel CART in Multiple Myeloma
In discussion with Dr. Jens Hillengasss from Roswell Park Comprehensive Cancer Center, covering the Multiple Myeloma key Experts discussed what to expect from CAR T-cell therapy for multiple myeloma, autologous stem cell transplant, managing the
Learn about what multiple myeloma is, how it develops, and what kind of treatments are available. Please talk with your doctor NCCN Guidelines for Newly Diagnosed MM Dr. Anderson on How the Definition of Myeloma Has Changed
Shaji Kumar, ASCO 2018 – Advances in treatment approaches and guidelines for multiple myeloma Register now for the Virtual NCCN 2022 Annual Conference March 31 - April 2, 2022! Designed
What are the new NCCN/IMWG recommended baseline workup tests for multiple myeloma? During the 5th European Myeloma Network (EMN) Meeting, the Multiple Myeloma Hub was pleased to speak with Shaji Kumar, Register now for the NCCN Virtual Congress: Hematologic Malignancies™ October 14 - 16, 2021! New format
NCCN Animation for Patients: Metastatic Breast Cancer Testing Explained Recorded on February 15th, 2022 as part of the Selinexor Support Group Chapter in the Myeloma Crowd Community by Using Patient Cases to Mimic Workflow to Apply NCCN Guidelines for Multiple Myeloma Treatment
The NCCN Guidelines for Multiple Myeloma provide recommendations for diagnosis, initial workup, treatment, follow-up, and supportive care for patients with Join Us for the Virtual NCCN 2022 Annual Conference! | March 30 - April 2
In this video, Dr. Craig Cole explores a critical issue in multiple myeloma care: the inadequate representation of patients in the Symptoms and risks experienced by patients with multiple myeloma are described by cancer expert Kenneth C. Anderson, MD, Gina Columbus reports on promising findings in phase III melanoma and lung cancer studies, an FDA approval sought in
Multiple Myeloma: Symptoms, Treatment, and Patient Care - Ask Mayo Clinic Health System During the National Comprehensive Cancer Network (NCCN) 2021 Annual Conference, the Mutiple Myeloma Hub spoke to Risk Stratification for MGUS | Dr. S. Vincent Rajkumar | Oncology Brothers
What Are the Treatment Options for Patients With Lenalidomide-Refractory Myeloma? What are the NCCN guidelines? How and when should PET scans be used? What do they show? #myeloma
Experts provide an overview of CAR T-cell therapy for lymphoma and side effects. This webinar is designed for those with cancer, NEWLY DIAGNOSED MYELOMA, ROBERT ORLOWKSI The NCCN Multiple Myeloma Panel members have developed guidelines for the management of various plasma cell neoplasms.
How National Comprehensive Cancer Network (NCCN) Guidelines Help Pick the Best Myeloma Treatment Multiple Myeloma, Version 2.2024, NCCN Clinical Practice
Consider going to a cancer specialist, cancer center, or hospital experienced in treating people with multiple myeloma. Page 12. 10. NCCN Guidelines for Different cell types within myeloma have varying susceptibilities to different drug therapies, and some cells will not respond to
Donna Catamero, ANP-BC, OCN, CCRC, of the Icahn School of Medicine at Mount Sinai, discusses the efficacy and toxicity The BCMA Playbook in Multiple Myeloma
Multiple myeloma is a cancer of plasma cells, which are a typically located in the bone marrow. The bone marrow is the soft, Bone marrow transplantation approaches to treating multiple myeloma video
We catch up with our US Editor-in-Chief to discuss advances in molecular targets and treatment in multiple myeloma, as well as NCCN Animation for Patients: What is Multiple Myeloma? Multiple myeloma, which is a cancer of the bone marrow, is discussed by cancer expert Kenneth C. Anderson, MD, from
Presented on August 28, 2014 Sponsored by a grant from the National Comprehensive Cancer Network (NCCN) and Pfizer. Rafael Foseca, MD, reviews the NCCN guidelines for multiple myeloma and the transplant candidates VRD and KRD and
NCCN Guidelines® Insights: Multiple Myeloma, Version 3.2022 Why YOU Should Attend the NCCN Virtual Congress: Hematologic Malignancies™ │ October 14 - 16, 2021
Lisa Hwa Christenson, APRN, DNP, CNP, FAPO, and Miriam Hobbs, NP, emphasize the importance of patient cases to outline the What are the NCCN Guidelines and how do they help choose the right cancer treatment? The National Comprehensive Cancer